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Introduction. With the advent of immunotherapy, a new subtype of side effects called IRAEs or immune related adverse effects
have become more common. They may present in various organ systems as colitis, pneumonitis, hypophysitis, and thyroiditis and
commonly as dermatological reactions. Case. This is a case report of a lung cancer patient that was started on Pembrolizumab and
developed shortly after what appeared to be clinically at first pustular psoriasis but on biopsy was confirmed to be lichen planus.
She was discontinued on the Pembrolizumab and treated with both systemic and topical steroids and improved. Conclusion. This
case highlights a cutaneous reaction from Pembrolizumab and the subsequent management that helped resolve her condition but
also weighing the benefits against the risk of treatments and potential prognostic implications of having cutaneous side effects.
1. Introduction
Cancer growth has long been linked to the ability of malig-
nant cells to avoid detection by the patient’s own immune
system and leads to uninhibited growth. With increased
understanding of tumor immunity, new medications have
been developed to selectively target checkpoints in the
cell cycle known as checkpoint inhibitors. Some of the
most common targets include programed cell death protein
and ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte
associated protein-4 (CTLA-4) now utilized in metastatic
melanoma, lung cancer, and renal, gastric, and hepatocellular
carcinomas management [1, 2]. Activating and improving
the patient’s own innate immune system to recognize and
to act against cancer cells have led to improved outcomes
with less toxicity than traditional chemotherapy. However,
this has also led to nonspecific activation that causes a
new class of side effects known as immune-related adverse
side effects (IRAEs). Examples of the most common side
effects related to checkpoint inhibitors are colitis, diarrhea,
thyroiditis, and hypothyroidism with autoantibodies against
thyroid peroxidase or thyroid stimulating hormone receptors,
hypophysitis, pneumonitis, autoimmune hepatitis, and pol-
yarthralgia. Of these IRAEs, dermatological reactions are
the most common including pruritus, maculopapular rashes,
vitiligo, lichenoid skin reactions, psoriasis, and rarely life
threatening effects like bullous pemphigoid, Stevens-Johnson
syndrome, and drug rash with eosinophilia and systemic
symptoms (DRESS) [3, 4]. In this case report, the patient was
on Pembrolizumab and developed lichen planus and we will
discuss further its presentation, management, and potential
prognostic implications if patients have cutaneous side effects
from immunotherapy.
2. Case
This is a case of a 60-year-old female with stage IV T3N3M1
lung adenocarcinoma metastatic to adrenals and bone was
found to have EGF, ROS, ALK WT, and KRAS mutation
and lymphangitic disease. She initially received six cycles of
carboplatin and pemetrexed and then switched to mainte-
nance Alimta after three cycles. However, CT scans showed
progression of disease and she was switched to Nivolumab.
For dosing convenience for the patient, she was then switched
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Figure 1: Photograph of lichen planus lesions on the patient’s feet.
Figure 2: Skin biopsy shows a lichenoid lymphocytic infiltrate
with acanthosis, hyperkeratosis, hypergranulosis, and civatte bodies
(apoptotic basal keratinocytes).
to Pembrolizumab for every 3 weeks. Five months since
starting Pembrolizumab, the patient then developed a pru-
ritic rash on her wrists, feet, and buttocks and oral mucosal
lesions. She was given clobetasol ointment and benadryl but
on a follow-up visit a month afterwards she had developed
a worsening rash. It became more difficult to walk and on
physical exam the lesions appeared to be fluid filled and
weeping bilaterally on feet and hands with psoriasiform
papules, patches on back and buttocks, indurated pustules,
and plaques on palms and sole. It was initially diagnosed by
her dermatologist on clinical exam to be possibly pustular
psoriasis and the patient was then started on oral prednisone
20mg once a day and urea cream 40% twice a day and her
Pembrolizumabwas held. She improvedwithin the next week
but still had persistent maculopapular lesions on her feet
(Figure 1) and then a punch biopsy of a left thigh lesion
showed a diagnosis of palmoplantar lichen planus reaction
(Figure 2). After five months of stopping the Pembrolizumab
the rash started to decrease and her oral mucosal lesions
disappeared. One year after the first cycle of Pembrolizumab,
the patient now has healing hyperpigmented lesions with
residual pain where the prior lesions were with Nystatin-
Triamcinolone 10000-0.1 unit/gm external cream three times
a day andPembrolizumab is still being held. Furthermore, her
lung adenocarcinoma is currently well maintained and has
not progressed despite having Pembrolizumab being held and
no further treatment.
3. Discussion
Although there is a wide variety of IRAEs, cutaneous side
effects are the most commonly associated with checkpoint
inhibitors. In a study by Hofman et al. it has been reported
that 8.7% ofmelanoma patients treatedwith anti-PD1 therapy
developed primary adverse dermatological events [5]. Specif-
ically, Pembrolizumab, an IgG4 antagonist antibody to PD-1,
was associated with cutaneous adverse events in 42% of its
patients and 8 months from onset on average [6–9].
Lichen planus and lichenoid reactions are chronic inflam-
matory, T cell mediated reactions to an unknown anti-
gen seen in various medications including beta-blockers,
antimalarials, antihypertensive and proton pump inhibitors.
Clinically, lichenoid reactions have different subtypes based
on the sites it is involved with and morphology. Classically,
it presents as papular/plaques, purple, pruritic, polygonal,
and planar. Other types include hypertrophic that is com-
mon on extremities, vesiculobullous with blisters on lower
extremities, and palmoplantar lesions that are scaly, bilateral,
and symmetrical onmalleoli and internal plantar arch. Other
locations lichen planus can affect other than cutaneous loca-
tions are mucous membranes including oral, vulvovaginal,
conjunctival, and laryngeal/esophageal [10–15]. As in our
case, the patient presented with bullous vesicular lesions
originally thought to be pustular psoriasis due to the clinical
picture but found on biopsy to be ultimately lichen planus.
Moreover, the lesions were also found on her oral mucosa
along with flat papular polygonal lesions bilaterally on the
plantar arch and malleoli areas.
The mechanism of how this occurs is still unknown
but is thought to be T cell mediated. PD-1 itself is an
inhibitory molecule on T cells that have immune tolerance
to self-antigens and malignant tumors can express PD-L1 in
order to evade immune responses [10]. PD-1 is also involved
in epidermal preservation during inflammatory reactions
and, by blocking PD-L1, there is not only an increase in
the immune function of tumor-specific T cells but also an
unmasking effect of self-immunity or prior antigen immune
response. This leads to a widespread nonspecific T cell
activation with an increase in T cell and TCR binding
resulting in IRAEs in multiple organ systems and cutaneous
reactions. In lichenoid reactions, they specifically affect
keratinocytes expressing PD-L1 with lymphocyte infiltration
in subepithelium and necrosis of keratinocytes, dense CD4
positive and CD8 positive T cells, spongiotic dermatitis,
acanthosis, lymphocytic infiltrate of basal membrane, and
hypergranulosis [10–15]. Interestingly, lichenoid reactions are
not seen in other targeted therapies such as Ipilimumab,
Epidermal Growth Factor Receptor (EGFR) inhibitors like
Erlotinib and Bevacizumab or chemotherapies [9]. This may
indicate that cutaneous reactions are a target effect on PD-
1/PD-L1 pathway than nonspecific hypersensitivity reaction.
Treatment for cutaneous IRAEs in general is based
primarily on grade severity which is referredmost commonly
by The National Cancer Institute’s Common Terminology
Criteria for Adverse Events (CTCAE) [16] (Table 1). However,
psoriasis and lichenoid lesions were not specifically men-
tioned in CTCAE version 5.0 [16]. Furthermore, there is no
standardized treatment for many IRAEs and management is
based on case reports, case series, and expert consensus and
opinions. Generally, Grade 1 and 2 cutaneous reactions and
events are treated with topical corticosteroids and an oral
antipruritic or antihistamine. For Grade 3-4 a skin biopsy is
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Table 1: Skin and subcutaneous tissue disorders management of different gradings based on CTCAE (Common Terminology Criteria for
Adverse Events) [16].
Grading (CTCAE) General CutaneousFeatures Steroids Immunosuppressives
Management of
Immunotherapy
Outpatient or
Inpatient care
1 Covers <10% BSA,limited, asymptomatic Not recommended Not recommended Continue Outpatient
2
Covers 10-30% BSA,
minimal to moderate
symptoms
Topical or systemic
steroids oral 0.5-1
mg/kg/d
Not recommended Continue Outpatient
3
Covers >30% BSA,
moderate or severe
symptoms, limiting
self-care ADLs
Systemic steroids oral
or IV 1-2 mg/kg/d for
3 days then to
1mg/kg/d
Can consider if
unresolved after 3-5
days of steroids
Suspend, discuss
risk/benefit with
patient
Outpatient or
Inpatient for IV
steroids
4
>30% BSA and
fluid/electrolyte
abnormalities
Systemic IV
methylprednisolone
1-2mg/kg/d for 3 days
Can consider if
unresolved after 3-5
days of steroids
Discontinue
permanently
Inpatient and possible
ICU or burn unit
BSA: body surface area.
needed for classification and systemic steroids are needed for
at least 2-4 weeks. Steroids can be gradually reduced over 1
month if there is a responsewithmost IRAEs resolvingwithin
6-12 weeks [17]. Furthermore, cessation of immunotherapy
(temporary or permanent) is needed with these high-grade
reactions [5, 18, 19]. Lastly is the case of being refractory to
steroids, immunomodulatory or immunosuppressive agents
such as TNF-alpha (tumour necrosis factor) antagonists,
azathioprine, and MMF (mycophenolate mofetil) [20, 21].
In terms of specifically for lichenoid reactions the main
management includes topical and systemic corticosteroids
[22]. The majority are able to be maintained on their anti-
PD1 therapy (81%) and it was concluded that treatment can
still be continued [23]. Furthermore, it has been reported
that the majority respond well to topical steroids and holding
immunotherapy may not be needed in contrast to more
severe immunobullous toxicities [24]. Evidence of reduced
efficacy of immunotherapy with immunosuppressive medi-
cations is mixed and no definitive conclusions [25, 26] and it
is preferred still especially in high-grade cutaneous toxicity
as it can enable reinitiation of immunotherapy [25]. In this
atypical case of lichen planus, the lesions were initially severe
enough to cause our patient substantial clinical effects and
concerning features of bullous lesions that were resistant to
topical steroids that oral steroids were needed and cessation
of therapy in order for it to finally resolve.
Many of the cutaneous lichenoid side effects resolve
within 6 months to 1 year. However, it can also reoccur and
have periods of waxing and waning depending on different
subtypes including erosive lichen planus or hypertrophic
variants [27]. In terms of prognosis, cutaneous side effects
have also been shown as potential positive prognostic factors.
A study by Sanlorenzo et al. had examined a sample of
patients treated with Pembrolizumab who had cutaneous
adverse effects and their survival analysis showed that those
who had cutaneous adverse effects had longer progression
free intervals irregardless of treatment regimens [6]. Another
study by Freeman et al. involved Nivolumab and metastatic
melanoma patients and also showing a longer progression
free survival compared to those who did not experience cuta-
neous toxicity [28]. Furthermore, adverse cutaneous effects
such as hypopigmentation and vitiligo have been shown to be
possible positive prognostic factors but mainly in melanoma
patients [29–31]. However, what could potentially affect these
findings is that patients who progress with immunotherapies
like pembrolizumab or nivolumab would not have the same
cumulative amount compared to those who do not progress
and continue taking it.Thus, those that stay on treatment have
a higher chance of developing a cutaneous adverse effect and
may have a longer progression-free survival.
Lastly, there is controversy over whether oral lichen
planus is a potential risk factor for oral squamous cell
carcinoma (SCC). It has been debated that since oral lichen
planus has been shown to have had a loss of heterozygosity
and microsatellite instability and possible risk of malignant
transformation [32]. Further, it was shown that 2.4% of oral
lichen planus patients developed oral SCC in previously
treated areas [33] with transformation ratios ranging from
1% to 5% [34, 35]. However, there is a need to have larger
prospective cohort studies and further studies.
4. Conclusion
As for this patient in this case report she had developed
a lichen planus eruption after 3 months of an anti-PD-
L1 treatment, Pembrolizumab. Management for her case
included topical treatment that initially failed and then
systemic treatment with steroids and cessation of Pem-
brolizumab which eventually led to the resolution of the
rashes and cutaneous lesions. This case highlights how
different ways cutaneous side effects can be managed and
present as and the subsequent difficulties based on clinical
exam alone. Recognizing toxicities from immune checkpoint
therapies becomes increasingly important as the number
of patients on these treatments continues to grow and
decisions on whether to stop or continue immunotherapies
continue to be based on clinical experience as the field
4 Case Reports in Dermatological Medicine
advances. Side effects such as vitiligo and hypopigmentation
have been shown to be potentially prognostic and future
studies should examine if other cutaneous findings can be
also.
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